Medical Cannabis for Fibromyalgia: What the Larger CBD Trial Changes

Medical cannabis collection · Sources reviewed 11 October 2026

Fibromyalgia is a useful test of whether a promising treatment survives better research. Earlier reports of cannabis-based treatment often described improvements in pain, sleep or quality of life. A larger, longer trial of CBD subsequently found less pain improvement with CBD than with placebo. Both parts of that history belong in an honest account.

Why the earlier literature looked encouraging

A 2024 systematic review assembled 19 publications concerning cannabis-based products and fibromyalgia. These included different kinds of evidence and a variety of products. Improvements in pain and other symptoms were reported, but the review also identified the need for stronger research. Lopera and colleagues, 2024.

A collection of favourable reports can be a reason to investigate a treatment. It is less dependable as a prediction of what would happen if comparable patients received the treatment or a convincing placebo. Changing symptoms, additional care, expectations and the selective continuation of treatment can all influence an uncontrolled result.

The larger CBD trial

Rasmussen and colleagues randomly assigned 200 adults at a Danish specialist clinic to CBD tablets, 50 mg daily, or placebo for 24 weeks. The study was published online in August 2025 and appeared in the March 2026 issue of Annals of the Rheumatic Diseases. This was a defined medicine regimen, not a comparison of every cannabis product. The randomised trial.

On the 0–10 pain scale, average improvement was 0.4 points with CBD and 1.1 points with placebo. The between-group result favoured placebo and was statistically significant. Adverse effects were generally mild and similarly distributed. The tested dose is a description of the research, not a suggested personal prescription.

“The findings do not support CBD 50 mg daily as an analgesic supplement for patients with fibromyalgia.”

Rasmussen et al., online 2025; print 2026

The conclusion applies to the regimen studied. Increasing the dose is another hypothesis, not a benefit demonstrated by this trial.

A placebo response does not make pain imaginary

The placebo group received more than an inert tablet: participants also had study contact, assessments and the experience of taking part in treatment. Symptoms can fluctuate, and people may enter a study during a particularly difficult period. Randomisation helps distinguish the additional effect of the tested medicine from changes shared by the groups.

For the patient, an improvement is still an improvement. For a claim about CBD, the relevant comparison is whether it adds enough benefit over the comparator to justify its costs and burdens. Those are different questions, and neither requires doubting someone’s account of pain.

What about THC-containing cannabis?

A small 2019 crossover experiment tested three vaporised cannabis preparations and placebo in 20 people with fibromyalgia. Measurements were made over three hours after a single inhalation session. No preparation outperformed placebo on average spontaneous or electrically evoked pain responses; THC-containing preparations increased pressure-pain thresholds. One preparation produced more participants reaching a 30% reduction in spontaneous pain, and pain changes were associated with the reported high. Van de Donk and colleagues, 2019.

These mixed findings are more informative than a simple positive or negative label. A laboratory pressure threshold is not the same outcome as sustained everyday pain, sleep, work or physical function. An acute experiment cannot establish that a treatment remains useful and tolerable for months.

What a useful next trial would need

The negative CBD trial narrows the claim that can responsibly be made. It also helps prevent a familiar research mistake: treating every encouraging observation as confirmation while treating an unfavourable controlled trial as irrelevant. Future findings may change the picture, but they should meet the same evidential standard.

A clinical discussion can start with the person’s most limiting difficulties and the outcomes that would make treatment worthwhile. Pain, fatigue, sleep and participation deserve separate attention. A treatment that changes a pain score while leaving daily life unchanged has answered only part of the question.

Educational information, not an individual prescribing plan. Decisions about medicines belong with the treating clinician. External reference links open in a new tab.